U.S. pharmaceutical company Gilead Sciences has announced a partnership with the biopharmaceutical company Arcus Biosciences!
On May 31, Gilead Science Company (GILD) official news, May 27, 2020, US time, Gilead Science and focus on the field of oncology, dedicated Arcus Biosciences, a biopharmaceutical company that creates first-class cancer immunotherapy, announced that the two parties have established a 10-year partnership to jointly develop and commercialize existing and future candidate therapeutic products in the Arcus research and development pipeline.
According to the terms of the agreement, Arcus will receive US $ 375 million, including an upfront payment of US $ 175 million and a US $ 200 million equity investment from Gilead. As far as current clinical candidates are concerned, Arcus is eligible to receive up to $ 1.225 billion in opt-in and milestone payments. In addition, Gilead will further provide up to US $ 400 million in continuous R & D support during the cooperation period, totaling US $ 2 billion.
Arcus Biosciences is a biopharmaceutical company specializing in oncology, with a variety of oncology products.
AB928 is the first and only clinical dual A2a / A2b adenosine receptor antagonist, currently being evaluated in multiple Phase 1b / 2 studies, which involves Multiple indications, including prostate cancer, colorectal cancer, non-small cell lung cancer, pancreatic cancer, triple negative breast cancer, and renal cell carcinoma.
AB680 is the first clinically small molecule CD73 inhibitor and is currently in the first-stage development of first-line treatment of metastatic pancreatic cancer. Anti-TIGIT monoclonal antibody AB154 is in the second phase of random research and development. It is used in combination with zimberelimab and AB928 for the first-line treatment of metastatic non-small cell lung cancer.
Zimberelimab (AB122) is Arcus ’anti-PD-1 monoclonal antibody, and a phase 1b study is evaluating its anti-PD-1 treatment options that have not yet been approved Use as a monotherapy for cancer and its combination with other drugs in the product line.
According to Gilead Scientific, as Gilead continues to expand its business in the field of oncology, Gilead will acquire Arcus ’current and future research immune tumors through this agreement Products, including the direct right of zimberelimabLi, as well as the right to opt-in for all other Arcus clinical products, including AB154, AB928 and AB680. After delivering the qualified data package, Gilead will have to pay an optional join fee ranging from US $ 200 million to US $ 275 million for each project. If Gilead chooses to join the AB154 project, Arcus will receive a milestone payment of up to $ 500 million when it receives future US regulatory approval.
In the next ten years, Gilead will have the right to choose to join all other projects brought by Arcus ’research portfolio. After Arcus delivers the qualified data package, Gilead needs to Pay the $ 150 million opt-in fee for each project.
Daniel O’Day, Chairman and CEO of Gilead Science, said: “Gilead Science is committed to achieving the world ’s top innovative breakthrough in the field of immuno-oncology, Gilead The cooperation between Science and Arcus will be refined. Gilead Science will continue to improve in the research and development of immuno-oncology. By acquiring Arcus’s extensive and diversified pipelines and its significant advantages in research and development, we believe this cooperation will significantly accelerate Progress in the development of innovative cancer treatments. “
According to official Gilead information, Gilead has eight innovative medicines listed in China, covering hepatitis B, hepatitis C and HIV / AIDS Areas to help address unmet medical needs in these areas. During the new crown epidemic, Gilead’s Ridesivir once became the hope of China and even the world.